Alnylam Licenses RNAi Patents to Qiagen

Alnylam Pharmaceuticals said this week that it has granted Qiagen non-exclusive access to use technology covered under the Kreutzer-Limmer patent family to provide RNAi research products and services.

The intellectual property covers small interfering RNAs and their use to mediate RNAi in mammalian cells.

Qiagen already offers siRNA libraries and high-throughput siRNA synthesis technology.


Galapagos to Acquire BioFocus for $36.5 Million in Stock

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.